Welcome to our dedicated page for Scholar Rock Holding SEC filings (Ticker: SRRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking clinical milestones, cash runway, and insider sentiment at Scholar Rock shouldn’t require dissecting hundreds of biotech-specific disclosures. From complex revenue-sharing notes to detailed Phase II trial updates, Scholar Rock’s SEC filings pack dense science and accounting into every page—exactly where critical investment signals hide.
Stock Titan’s platform solves the problem. Our AI reviews each Scholar Rock annual report 10-K simplified and every Scholar Rock quarterly earnings report 10-Q filing, surfacing what matters—R&D expense trends, milestone payment schedules, and liquidity forecasts—in plain language. Need fast context on an unexpected trial update? The moment an 8-K posts, you’ll see “Scholar Rock 8-K material events explained” beside a concise summary. Curious about executive confidence levels? Real-time alerts tie each Scholar Rock Form 4 insider transactions to market dates so you can spot buying or selling before the next catalyst.
All filings are indexed and searchable:
- Form 4 feeds for Scholar Rock insider trading Form 4 transactions and Scholar Rock executive stock transactions Form 4
- 10-K, 10-Q, and 8-K documents with line-item AI commentary for quick Scholar Rock earnings report filing analysis
- DEF 14A proxy reports highlighting Scholar Rock proxy statement executive compensation
Whether you’re understanding Scholar Rock SEC documents with AI or comparing cash burn across quarters, our expert-trained algorithms and real-time EDGAR feeds give you the clarity to act decisively—no advanced biology degree required.
Jeffrey S. Flier, Director of Scholar Rock Holding Corp (SRRK), executed several transactions on June 23, 2025, as part of a pre-planned Rule 10b5-1 trading plan established on February 27, 2025:
- Exercised 20,316 stock options at $21.62 per share
- Sold 17,550 shares at weighted average price of $32.16
- Sold 2,766 shares at weighted average price of $32.74
- Sold 11,136 shares at weighted average price of $33.21 (held in family trust)
Following these transactions, Flier directly owns 24,070 shares (including 16,438 common shares and 7,632 RSUs) and indirectly owns 11,136 shares through The Jeffrey S. Flier Family Trust - 2014. The exercised stock option has no remaining unvested shares. These transactions represent a significant reduction in Flier's direct holdings, suggesting potential portfolio rebalancing or profit-taking with the stock trading above $32.
FAQ
What is the current stock price of Scholar Rock Holding (SRRK)?
What is the market cap of Scholar Rock Holding (SRRK)?
What is the primary focus of Scholar Rock Holding Corporation?
Which therapeutic areas does Scholar Rock target?
How does Scholar Rock differentiate itself in the biopharmaceutical industry?
What role do growth factors play in Scholar Rock’s therapeutic approach?
Who are the scientific leaders behind Scholar Rock?
How is Scholar Rock’s business model structured?
What competitive advantages does Scholar Rock offer?
Does Scholar Rock engage in partnerships?
